Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
Ferrante
K L
KL
Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kimberly.ferrante@umassmed.edu
Shefner
J
J
Zhang
H
H
Betensky
R
R
O'Brien
M
M
Yu
H
H
Fantasia
M
M
Taft
J
J
Beal
M F
MF
Traynor
B
B
Newhall
K
K
Donofrio
P
P
Caress
J
J
Ashburn
C
C
Freiberg
B
B
O'Neill
C
C
Paladenech
C
C
Walker
T
T
Pestronk
A
A
Abrams
B
B
Florence
J
J
Renna
R
R
Schierbecker
J
J
Malkus
B
B
Cudkowicz
M
M
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D003067:Coenzymes; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D009410:Nerve Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D014451:Ubiquinone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood
D003067:Coenzymes; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D014451:Ubiquinone; C024989:coenzyme Q10